These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 18804182)
41. High-throughput identification of molecular targets of brain disorders using antibody-based microarray analyses. Gu Q Expert Rev Neurother; 2008 Sep; 8(9):1281-3. PubMed ID: 18759538 [No Abstract] [Full Text] [Related]
42. [Therapeutic experiment on mouse cancer with a cancer antigen]. HECHT H Oncologia; 1955; 8(1):46-54. PubMed ID: 14394615 [No Abstract] [Full Text] [Related]
43. Isolation of a cancer-specific antigen. LUND H Dan Med Bull; 1955 May; 2(3):73-82. PubMed ID: 14379741 [No Abstract] [Full Text] [Related]
44. Diversity-Based Organic Synthesis in the Era of Genomics and Proteomics NRC publication no. 43843. David Thomas is a senior colleague and mentor. Arya P; Chou DT; Baek MG Angew Chem Int Ed Engl; 2001 Jan; 40(2):339-346. PubMed ID: 11180320 [No Abstract] [Full Text] [Related]
45. [Antibody formation and cancer growth]. SEELICH F Wien Klin Wochenschr; 1954 Sep; 66(35-36):635-8. PubMed ID: 14348839 [No Abstract] [Full Text] [Related]
46. HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens. Xu QW; Zhang Y; Wang XS Oncoimmunology; 2013 Mar; 2(3):e23249. PubMed ID: 23802073 [TBL] [Abstract][Full Text] [Related]
47. [Fixation of antigens on cell surface]. DE GREGORIO M Boll Ist Sieroter Milan; 1955; 34(3-4):118-22. PubMed ID: 14389466 [No Abstract] [Full Text] [Related]
49. Prioritization of cancer antigens: keeping the target in sight. Lang JM; Andrei AC; McNeel DG Expert Rev Vaccines; 2009 Dec; 8(12):1657-61. PubMed ID: 19943761 [No Abstract] [Full Text] [Related]
50. Mapping the surface of the cancer cell. Nature; 1971 May; 231(5299):148. PubMed ID: 16062599 [No Abstract] [Full Text] [Related]
51. Multiple Tolerization Subtractive Immunization (MTSI) Protocol: Effects on Mice and Monoclonal Antibody Specificity. de Lima Fontes M; Neves FML; Santos KS; Fusco-Almeida AM; Giannini MJSM; Felisbino SL; Deffune E; Moroz A Front Immunol; 2021; 12():760817. PubMed ID: 34950138 [TBL] [Abstract][Full Text] [Related]
52. Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach. Lisini D; Lettieri S; Nava S; Accordino G; Frigerio S; Bortolotto C; Lancia A; Filippi AR; Agustoni F; Pandolfi L; Piloni D; Comoli P; Corsico AG; Stella GM Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445720 [TBL] [Abstract][Full Text] [Related]
53. 4H12, a Murine Monoclonal Antibody Directed against Myosin Heavy Chain-9 Expressed on Acinar Cell Carcinoma of Pancreas with Potential Therapeutic Application. Balouchi-Anaraki S; Ahmadvand S; Safaei A; Ghaderi A Iran Biomed J; 2021 Sep; 25(5):310-22. PubMed ID: 34425650 [TBL] [Abstract][Full Text] [Related]
54. Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using RNA-Seq Technologies. Rassek K; Iżykowska K Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751918 [TBL] [Abstract][Full Text] [Related]
55. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Li H; Er Saw P; Song E Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210 [TBL] [Abstract][Full Text] [Related]
56. Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer. Yuan D; Chen H; Wang S; Liu F; Cheng Y; Fang J Cancer Med; 2018 Oct; 7(10):5155-5166. PubMed ID: 30277651 [TBL] [Abstract][Full Text] [Related]
57. Guiding nanomaterials to tumors for breast cancer precision medicine: from tumor-targeting small-molecule discovery to targeted nanodrug delivery. Qu X; Qiu P; Zhu Y; Yang M; Mao C NPG Asia Mater; 2017; 9():. PubMed ID: 29657602 [TBL] [Abstract][Full Text] [Related]
58. Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448. Cua S; Tan HL; Fong WJ; Chin A; Lau A; Ding V; Song Z; Yang Y; Choo A Oncotarget; 2018 Mar; 9(17):13206-13221. PubMed ID: 29568351 [TBL] [Abstract][Full Text] [Related]
59. Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug. Bemani P; Mohammadi M; Hakakian A Asian Pac J Cancer Prev; 2018 Jan; 19(1):97-102. PubMed ID: 29373898 [TBL] [Abstract][Full Text] [Related]
60. Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers. Kurosawa Y J Stem Cells Regen Med; 2011; 7(1):14-28. PubMed ID: 24693169 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]